1core refs 4审查综合抗逆转录治疗对艾滋病毒感染副作用蒙特.pdfVIP

Review Synthèse Adverse effects of antiretroviral therapy for HIV infection Valentina Montessori, Natasha Press, Marianne Harris, Linda Akagi, Julio S.G. Montaner the protease inhibitors (PIs). The NNRTI class comprises LONG-TERM REMISSION OF HIV-1 DISEASE CAN BE READILY ACHIEVED by combinations of antiretroviral agents. The suppression of sma viral loads to less than the limit of fication of the mos - sitive commercially available assays (i.e., less than 50 copies/mL) and the co improvement D4 T cell counts is associ- ated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to pa- tient. A better understanding of the adverse effects of antiretrovi- ral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV- positive patients. CMAJ 2004;170(2):229-38 he introduction of highly active antiretroviral ther- apy (HAART) has led to a significant reduction in TAIDS-related morbidity and mortality.1–3 Unfortu- na y, up to 25% of patients discontinue their initial HAART regimen because of treatment failure (inability to suppress HIV viral replication to below the current limit of detection, 50 copie